RxDoctor Payments Data

Michelle Sedlacek, PA

Physician Assistant · Scottsdale, AZNPI 1013169135

Payments from drug & device makers

$4,035in general payments, 2019–2025

Across 175 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$449
  • Sumitomo Pharma America, Inc.$414
  • Astellas Pharma US Inc$342
  • Johnson & Johnson$318
  • Progenics Pharmaceuticals, Inc.$284
  • Dendreon Pharmaceuticals LLC$261
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$3,83995%
  • Education$1965%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,035 in reported general payments places this provider in the 85th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$103,155
Medicare patients
651
Services billed
4,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron43$44,123
GemtesaVibegron29$34,088
Potassium Citrate ErPotassium Citrate48$6,144
Testosterone19$5,284
Tamsulosin Hcl300$4,376
Finasteride282$4,051
Dutasteride66$3,313
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst57$3,239
Estradiol24$2,645
Solifenacin Succinate52$2,467
Methenamine Hippurate17$2,098
Tadalafil11$2,025
Testosterone Cypionate45$1,938
Cephalexin65$1,637
NitrofurantoinNitrofurantoin Macrocrystal31$1,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$342$44,12343 claims
Sumitomo Pharma America, Inc.Gemtesa$414$34,08829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →